KR102991384B1 - 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis) - Google Patents

조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis)

Info

Publication number
KR102991384B1
KR102991384B1 KR1020227039203A KR20227039203A KR102991384B1 KR 102991384 B1 KR102991384 B1 KR 102991384B1 KR 1020227039203 A KR1020227039203 A KR 1020227039203A KR 20227039203 A KR20227039203 A KR 20227039203A KR 102991384 B1 KR102991384 B1 KR 102991384B1
Authority
KR
South Korea
Prior art keywords
triiodothyronine
sepsis
pharmaceutical composition
administration
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227039203A
Other languages
English (en)
Korean (ko)
Other versions
KR20230022839A (ko
Inventor
콘스탄티노스 판토스
로다니스 모로지스
Original Assignee
유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이.
세티, 줄리아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by 유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이., 세티, 줄리아 filed Critical 유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이.
Publication of KR20230022839A publication Critical patent/KR20230022839A/ko
Application granted granted Critical
Publication of KR102991384B1 publication Critical patent/KR102991384B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227039203A 2020-04-21 2021-04-15 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis) Active KR102991384B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GR20200100200 2020-04-21
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695 2020-11-23
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216 2021-03-29
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (2)

Publication Number Publication Date
KR20230022839A KR20230022839A (ko) 2023-02-16
KR102991384B1 true KR102991384B1 (ko) 2026-07-14

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039203A Active KR102991384B1 (ko) 2020-04-21 2021-04-15 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis)

Country Status (13)

Country Link
US (1) US12673036B2 (cg-RX-API-DMAC7.html)
EP (1) EP4138810A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023538984A (cg-RX-API-DMAC7.html)
KR (1) KR102991384B1 (cg-RX-API-DMAC7.html)
CN (1) CN115996710B (cg-RX-API-DMAC7.html)
AU (1) AU2021258544A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021250A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176106A1 (cg-RX-API-DMAC7.html)
GE (2) GEP20247706B (cg-RX-API-DMAC7.html)
IL (1) IL297398B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013228A (cg-RX-API-DMAC7.html)
WO (1) WO2021214497A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202212502B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024919A1 (en) * 1994-03-15 1995-09-21 K.U. Leuven Research & Development New use of growth hormone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US20050059574A1 (en) 2000-12-21 2005-03-17 Irwin Klein Compositions of stable T3 and methodes of use thereof
JP2004525874A (ja) 2000-12-21 2004-08-26 リサスサイテック, インコーポレイテッド 安定したt3の組成物およびその使用方法
US8404281B2 (en) 2009-06-08 2013-03-26 Avant Garde Therapeutics & Technologies Llc Formulations
CN103705497B (zh) 2013-12-11 2015-04-01 武汉威立得生物医药有限公司 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
EP3908272B1 (en) 2019-01-09 2023-03-22 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-triiodothyronine (t3) for use in limiting microvascular obstruction
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
GR1010182B (el) 2020-11-23 2022-03-01 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR1010068B (el) 2020-04-21 2021-09-01 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024919A1 (en) * 1994-03-15 1995-09-21 K.U. Leuven Research & Development New use of growth hormone

Also Published As

Publication number Publication date
BR112022021250A2 (pt) 2022-12-06
ZA202212502B (en) 2024-05-30
IL297398B2 (en) 2026-05-01
IL297398B1 (en) 2026-01-01
IL297398A (en) 2022-12-01
KR20230022839A (ko) 2023-02-16
US12673036B2 (en) 2026-07-07
GEP20247706B (en) 2024-12-10
US20230157982A1 (en) 2023-05-25
AU2021258544A1 (en) 2022-10-27
MX2022013228A (es) 2022-11-14
WO2021214497A1 (en) 2021-10-28
CN115996710B (zh) 2024-06-28
EP4138810A1 (en) 2023-03-01
CA3176106A1 (en) 2021-10-28
JP2023538984A (ja) 2023-09-13
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)